Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."

01 Oct 2017


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:




Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"


BlumenthalAntiTrust Lawsuit

Exosomes, Blebs


CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994

Pathogenic Fungi

Bush's warcrimes, Oct 2000




CHAPTER 6  of Cryme Disease (Nov, 2007)

The Lyme Crooks' RICO patents tell a very different story from their public one...

This is data the Lyme crooks (Yale/NYMC/ALDF/IDSA/Kaiser cabal) refused to turn over to the Connecticut Attorney General for a year and a half before settling out of court.

1) Yale's Bb Flagellin Patent (an FDA-validated method), 5.618,533 
2) Yale's LYMErix Patent, 5,747,294
Their validated method was not used to assess their LYMErix patent.

3) Padula, UCONN, 5,620,862  B31 = Low or No OspC- associated with brain invasion
4) CDC officer Alan Barbour and "Immune System is  Overhwhelmed," US Patent 6,719,983- (because Lyme is relapsing fever and the nature of the relapse is that antibodies do no good)
5) Tufts, Huber, 6,689,364 "LYMErix is a toxin"
6) Persing, Mayo Clinic, Monopoly Patent-6,045,804
7) CDC's patents with SmithKline in Europe which shows they know the Steere method is bogus.

8) Barbour's flagella-less borrelia patent
9) 1996 B. theileri patent (Master's Disease is Cow Relapsing Fever Alan Barbour patent application for Masters' Disease 5,932,220


How to verify-  How to use the US Patent Database:  US Patent Office  Main Search page  Patent Number Search page



1) Yale explains how LYMErix does not work:

2) Yale not using DNA primers for flagellin to determine OspA "works":

They should not have used immunofluorescing antibodies, because OspA would no longer around due to "selection pressure"

3)  Yale discussing how LYMErix does not prevent Lyme because of the selection pressure, which essentially means that Lyme is a relapsing fever borreliosis, since they all are relapsing fever borrelioses.   4 days previously Yale applied for the LYMErix patent- even though they knew LYMErix did not work:



1) Yale's Bb Flagellin Patent, 5.618,533  94.4% accurate, earliest, and likely nearly 100% specific, or is the best antibody test for Lyme Borreliosis.

The Yale report that goes with the patent (1991):


2) Yale's LYMErix Patent, 5,747,294, Yes I know these by heart  Check out the date the patent was applied for.  It was 4 days before Yale sent for publication, the article where they explain how LYMErix would not work.


3) Padula, UCONN, 5,620,862  Low or No OspC.  Yet SmithKline and Quest used/use B31, which means OspA, B and C will not be identified if you have those antbodies, and they are the "primary immunodominant antigens."

"In another aspect of the invention, Northern blot analysis was used to detect low levels of OspC mRNA in the North American strain B31. DNA sequencing of the OspC gene from B31 revealed a 54 bp deletion in the upstream regulatory region, possibly accounting for the low transcriptional activity of OspC."


That SmithKline and Quest use strain B31 is a crime, especially since the IgM method allowed by Dearborn allows two of the following three antibodies: 41, 39 and 23, which is OspC.


4) Barbour and "Immune System Overhwhelmed," US Patent 6,719,983-

"2.1 Methods of Treatment

"An important aspect of the invention is the recognition that Borrelia VMP-like sequences recombine at the vls site, with the result that antigenic variation is virtually limitless. Multiclonal populations therefore can exist in an infected patient so that immunological defenses are severely tested if not totally overwhelmed."


That means the Yale/Steere/Dearborn method is useless for people who do not have Steere's haplotypes.


5)  Tufts, Huber, 6,689,364

"The present invention provides novel polypeptides which are substantially free of a B. burgdorferi spirochete or fragments thereof and which are thus useful in compositions and methods for the treatment and prevention of B. burgdorferi infection and Lyme disease. In one preferred embodiment, this invention provides modified OspA polypeptides and pharmaceutically effective compositions and methods comprising those polypeptides. Preferred modified OspA polypeptides are characterized by modifications which diminish and/or ablate their ability to bind the human MHC allele HLA-DRB1*0401."

Means, basically, "superantigen."  (Look up what that means)



6)  The RICO Monopoly on testing and LYMErix  The Dave Persing, Mayo Clinic FRAUD Patent-6,045,804  Note the date on the patent.  May, 1996.

"Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure."

"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "


(Or, appropriate for a monopoly on vaccines and testing.)


Persing, Sigal and Molloy, 2000, and the unreadable blots


Here is Yale's Robert Schoen instructing physicians to blow off LYMErix injured persons and not run any tests on them.  This is the 1998 Rahn and Evans textbook Lyme disease, ACP Key Diseases Series.  This was published even before LYMErix was "approved" by the FDA.  Schoen also demonstrates that he knows that you can't use a strain of Bb with the OspA-B plasmid in it, because it causes blot smudging or IS A SUPERANTIGEN???

The vaccine did not come off the market until Karen Forschner of the Lyme disease Foundation demonstrated the Huber Tufts patent above to the FDA and that they KNEW this vaccine was dangerous.



    27)  Martin J. Mattessich    President & CEO, Director      “Prior to becoming President and CEO of Agilix, from 1996 to 1999 Mr. Mattessich was the co-founder of two Yale University-sponsored biotechnology companies, L2 Diagnostics, LLC (diagnostic serology) and polyGenomics, Inc. (gene discovery for polygenic diseases) , and a consultant to CuraGen Corporation, a publicly held genomics company (pharmaceutical drug ….” 

With the blood he intended to get from the L2 Diagnostics-Imugen nationwide monopoly on testing, they can identify new diseases to commercialize.   AND genetic susceptibilities to diseases.



CHAPTER 8, RUSSIAN SCIENTISTS AT NYMC (speaking about their "non-intracellular intracellular spheroplasts")


As we Lyme warriors cannot engage any earthly assistance;
As the entire US medical community chooses not to assist sick and abused people and put a stop to this;
As there is not one MD or group in the entire USA who will take these criminals to court;
As there is not one lawyer or Department of Justice official who will do the job they were hired to do and protect us from corporate crime;
As there are no men left among us:

Saint Michael the Archangel,
defend us in battle.
Be our protection against the wickedness and snares of the devil.
May God rebuke him, we humbly pray;
and do Thou, O Prince of the Heavenly Host -
by the Divine Power of God -
cast into hell, satan and all the evil spirits,
who roam throughout the world seeking the ruin of souls.